Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Non-invasive Neuromodulation Treatments for Post-COVID-19 Sequelae in Patients With Musculoskeletal, Respiratory and Neurological Conditions Due to Impaired Taste and Smell.

NCT06544395 is registered in ClinicalTrials.gov with Clinica Gema Leon as lead sponsor.

NCT NCT06544395
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06544395 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Non-invasive Neuromodulation Treatments for Post-COVID-19 Sequelae in Patients With Musculoskeletal, Respiratory and Neurological Conditions Due to Impaired Taste and Smell.
Lead sponsor
Clinica Gema Leon
Phase
Not applicable
Overall status
Not yet recruiting
Start date
January 1, 2026
Completion date
December 30, 2026
Enrollment
104 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 recurrent